Novo's Oral Wegovy Outpaces Lilly, But Pricing Pressure Looms

What happened

Novo Nordisk's oral Wegovy launched in early 2026 and quickly gained strong traction, with over 265,000 weekly U.S. prescriptions and 5 million cumulative scripts by early August, while Eli Lilly's competing pill Foundayo has been slower to gain acceptance. The master report indicates that while oral Wegovy demand is robust, Novo faces significant pricing pressure from rebates, Medicare/Medicaid mix, and competition, leading management to guide for 0% to -6% constant-exchange-rate sales growth in 2026. Eli Lilly has secured coverage across the three largest PBMs, and employer coverage for obesity drugs has declined from 72% to 60%, which may limit the financial benefit of Novo's pill success. Novo's stock at $44.56 trades at a low valuation (P/E ~11) but the market is skeptical about monetization of the pill, given the August disappointment after a modest outlook raise. Upcoming catalysts, including the September 2026 Capital Markets Day and Q3 2026 prescription and pricing disclosures, will be critical for reassessing whether volume growth can stabilize share and net revenue.

Implication

Investors should monitor oral Wegovy's weekly prescriptions and dose mix, as sustained growth above 265k with higher-dose share above 30% would strengthen the case for revenue stabilization. However, the broader pricing environment remains challenging, with Lilly's PBM wins and declining employer coverage likely capping net price realization. The current valuation appears to discount significant erosion, so evidence of pricing stabilization could lead to a re-rating toward the low $50s. Conversely, if Q3 data show stalled prescriptions or further price deterioration, the bear case of $36 becomes more likely. Near-term, the September Capital Markets Day is a key event for management to address pricing and persistence, which will determine whether the stock is attractive at current levels.

Thesis delta

The news article provides an additional data point that Novo's oral Wegovy is winning early adoption versus Lilly's Foundayo, reinforcing the demand side of the investment thesis. However, it does not change the core risk that pricing pressure and payer economics may still compress revenue growth despite strong volume. Consequently, the overall thesis remains a 'potential buy' hinging on evidence that oral Wegovy can stabilize obesity share and improve net revenue per patient, with the September Capital Markets Day and Q3 data as key checkpoints.